Results 11 to 20 of about 7,380 (205)
Questions about the antimalarial amodiaquine [PDF]
The Lancet, 2003 Sarah G. Staedke +2 more
+6 more sources
AMODIAQUINE AND COMBINATION CHEMOTHERAPY FOR MALARIA [PDF]
The American Journal of Tropical Medicine and Hygiene, 2005 Steven R. Meshnick, Alisa P. Alker
openalex +3 more sources
A pharmacokinetic–pharmacodynamic model for chemoprotective agents against malaria
CPT: Pharmacometrics &Systems Pharmacology, Volume 12, Issue 1, Page 50-61, January 2023., 2023 Abstract Chemoprophylactics are a vital tool in the fight against malaria. They can be used to protect populations at risk, such as children younger than the age of 5 in areas of seasonal malaria transmission or pregnant women. Currently approved chemoprophylactics all present challenges.
Mohammed H. Cherkaoui‐Rbati +9 more
wiley +1 more source
Amodiaquine-Associated Asthenia: A Case Based Review and Gaps in Literature [PDF]
International Journal of Travel Medicine and Global Health, 2016 Introduction: Amodiaquine is a partner drug in the artemisinin-based combination therapy artesunate-amodiaquine. Reports of the adverse drug reaction known as amodiaquine-associated asthenia are scarce, and this adverse reaction needs to be investigated ...
Obaro Michael +5 more
doaj +1 more source
Pharmacokinetics of intravenous amodiaquine. [PDF]
British Journal of Clinical Pharmacology, 1987 Amodiaquine hydrochloride (3 mg base kg‐1) was given by constant rate intravenous injection over 10 min to seven healthy adult male volunteers, and by constant rate infusion (10 mg base kg‐1) over 4 h to 10 adult patients admitted to hospital with falciparum malaria.
White, N +7 more
openaire +4 more sources
PLoS Medicine, 2021 BackgroundAmodiaquine is a 4-aminoquinoline antimalarial similar to chloroquine that is used extensively for the treatment and prevention of malaria.
Xin Hui S Chan +16 more
doaj +1 more source
Malaria Journal, 2021 Background Accurate measurement of anti-malarial drug concentrations in therapeutic efficacy studies is essential to distinguish between inadequate drug exposure and anti-malarial drug resistance, and to inform optimal anti-malarial dosing in key target ...
Thomas A. Anyorigiya +16 more
doaj +1 more source
Pharmaceutics, 2023 The objective of this study was to construct amodiaquine-loaded, folic acid-conjugated polymeric nanoparticles (FA-AQ NPs) to treat cancer that could be scaled to commercial production.
Vineela Parvathaneni +2 more
doaj +1 more source
Memorias do Instituto Oswaldo Cruz, 2006 There are wide variations in the threshold used to define in vitro resistance of Plasmodium falciparum to amodiaquine (AQ), probably due to differences in methodology and interpretation. In vitro susceptibility data of Colombian P.
Diego F Echeverry +3 more
doaj +1 more source
Malaria Journal, 2012 Background Several anti-malarial drugs are associated with adverse cardiovascular effects. These effects may be exacerbated when different anti-malarials are used in combination.
Adjei George O +6 more
doaj +1 more source